Accent Capital Management’s ImmunityBio IBRX Stock Holding History

Accent Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-331	Closed	-$2.54K	–	318
2026 Q1	$2.54K	Buy	+331	New	+$2.27K	﹤0.01%	316

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Accent Capital Management's IBRX Position: Q2 2026 in Review

Accent Capital Management sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 331 shares — an estimated $2.54K sold.

Accent Capital Management first reported a position in IBRX in Q1 2026 and held it in 1 quarter. The position peaked at $2.54K in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Accent Capital Management reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
Accent Capital Management sold 331 ImmunityBio shares in Q2 2026, an estimated $2.54K.
Accent Capital Management first reported a position in ImmunityBio in Q1 2026 and held it in 1 quarter.
Accent Capital Management's ImmunityBio position peaked at $2.54K in Q1 2026.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Accent Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.